UDP‐glucose dehydrogenase variants cause dystroglycanopathy
Abstract UDP‐glucose dehydrogenase (UGDH) variants have been associated with hypotonia, developmental delay, and epilepsy. We report the first pathologic evidence of dystroglycanopathy in siblings with UGDH variants. Both presented around 6 months with developmental delay and elevated creatinine kinase.
Anna M. Reelfs+8 more
wiley +1 more source
Engineering highly stable variants of Corynactis californica green fluorescent proteins. [PDF]
Hung LW+3 more
europepmc +1 more source
Broadband photon pair generation in green fluorescent proteins through spontaneous four-wave mixing. [PDF]
Shi S+5 more
europepmc +1 more source
Use of green fluorescent protein as a marker for ecological studies of activated sludge communities [PDF]
Leo Eberl
openalex +1 more source
Unleashing the Power of Multiomics: Unraveling the Molecular Landscape of Peripheral Neuropathy
ABSTRACT Peripheral neuropathies (PNs) affect over 20 million individuals in the United States, manifesting as a wide range of sensory, motor, and autonomic nerve symptoms. While various conditions such as diabetes, metabolic disorders, trauma, autoimmune disease, and chemotherapy‐induced neurotoxicity have been linked to PN, approximately one‐third of
Julie Choi+7 more
wiley +1 more source
Supercharged green fluorescent proteins as bimodal reporter genes for CEST MRI and optical imaging. [PDF]
Bar-Shir A+4 more
europepmc +1 more source
Visualising individual green fluorescent proteins with a near field optical microscope
M.F. Garcia Parajo+5 more
openalex +1 more source
Functional expression of green fluorescent protein derivatives in Halobacterium salinarum [PDF]
Sayuri Nomura
openalex +1 more source
Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier+8 more
wiley +1 more source